Loading...
XNAS
TLPH
Market cap8mUSD
Jun 10, Last price  
0.51USD
1D
-0.97%
1Q
-7.48%
Jan 2017
-99.02%
IPO
-99.42%
Name

AcelRx Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
45.53%
Rev. gr., 5y
-21.26%
Revenues
0k
-100.00%
0001,072,0002,394,00029,502,0005,217,00019,263,00017,357,0007,995,0002,151,0002,289,0005,416,0002,818,0001,771,000651,0000
Net income
-13m
L+26.41%
-20,662,000-20,119,000-14,344,000-20,101,000-33,363,000-23,426,000-33,353,000-24,399,000-43,157,000-51,508,000-47,149,000-53,240,000-40,379,000-35,099,00047,755,000-10,287,000-13,004,000
CFO
-13m
L-27.49%
-18,903,000-19,418,000-12,225,000-15,287,000-24,582,000-487,000-34,456,000-19,953,000-29,395,000-29,765,000-29,075,000-51,180,000-38,505,000-30,002,000-28,331,000-17,492,000-12,683,000

Profile

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
IPO date
Feb 11, 2011
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
651
-63.24%
1,771
-37.15%
Cost of revenue
6,718
5,546
7,784
Unusual Expense (Income)
NOPBT
(6,718)
(4,895)
(6,013)
NOPBT Margin
Operating Taxes
13
Tax Rate
NOPAT
(6,718)
(4,895)
(6,026)
Net income
(13,004)
26.41%
(10,287)
-121.54%
47,755
-236.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
27
8,856
7,671
BB yield
-0.20%
-0.08%
-45.82%
Debt
Debt current
7,464
Long-term debt
7,619
Deferred revenue
1,036
Other long-term liabilities
7,588
1,778
7,908
Net debt
(8,863)
(9,381)
(687)
Cash flow
Cash from operating activities
(12,683)
(17,492)
(28,331)
CAPEX
(100)
(364)
Cash from investing activities
3,781
(528)
36,450
Cash from financing activities
12,044
3,466
(507)
FCF
(6,718)
8,961
348
Balance
Cash
8,863
9,381
15,770
Long term investments
Excess cash
8,863
9,348
15,681
Stockholders' equity
(457,213)
(444,209)
(425,821)
Invested Capital
472,802
460,092
467,002
ROIC
ROCE
EV
Common stock shares outstanding
25,846
14,263,744
7,407
Price
0.52
-28.69%
0.74
-67.48%
2.26
-79.83%
Market cap
13,546
-99.87%
10,483,852
62,528.34%
16,740
-75.07%
EV
4,683
10,474,471
16,053
EBITDA
(6,839)
(4,584)
(4,366)
EV/EBITDA
Interest
394
134
1,153
Interest/NOPBT